In Brief: Pfizer
Pfizer: R&D budget will be $1.4 bil. in 1995, a greater than 20% increase, the company says March 16 in concert with release of its 1994 annual report. Pfizer says its commitment to R&D helped the company reach 1994 sales of $8.3 bil. worldwide and will continue to vault Pfizer to the top of the pharmaceutical industry. Combined worldwide sales of the company's newer products jumped 44% to $2.7 bil. last year...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth